AptarGroup: Active Materials Science Growth Driving Our Bullishness! 

AptarGroup Inc. (ATR) reported results for the fourth quarter and fiscal year 2024, highlighting a balanced performance across its segments while navigating through various market challenges. The company achieved core sales growth of 2% for the quarter, driven by robust demand in its Pharma segment, which saw strong sales in proprietary drug delivery systems for allergic rhinitis and emergency medicines. The reported adjusted earnings per share (EPS) of $1.52 exceeded expectations, aided by better operational performance and a favorable tax rate. For the full year, Aptar achieved 8% core sales growth in its Pharma segment, aligning with its long-term targets.